Supplementary Figure S2 shows the selection process. The Venn diagram showed that patient IDs among patients with high expression of both GREB1 and FKBP9 were clustered as BVZ-responsive GBM patients. The other patient IDs (highly expressed GREB1 or highly expressed FKBP9) were BVZ-non-responsive patients. Considering that these patients who received BVZ treatment relapsed after an average of 31 days, it is reasonable that 20% of patients in this group responded to BVZ treatment [33], even though the proportion was approximately 30%, based on previous AI and clinical studies [20,31,42]. This evidence concerns the gene GREB1 and glioblastoma.